ENOV
HealthcareEnovis Corporation · Medical - Devices · $1B
What is Enovis Corporation?
Enovis Corporation is a medical technology company focused on musculoskeletal health, serving orthopedic specialists, surgeons, physical therapists, and other healthcare professionals worldwide. Its products help patients recover from injuries, manage chronic conditions, and regain mobility.
Enovis develops, manufactures, and distributes medical devices targeting musculoskeletal conditions caused by degenerative diseases, deformities, trauma, and sports injuries. The company sells through independent distributors, healthcare professionals, retail stores, and pharmacies, as well as directly under its DJO brand. Revenue comes from two broad areas: prevention and rehabilitation products, and reconstructive joint implants for hips, knees, shoulders, and other joints.
Formerly known as Colfax Corporation, Enovis was established in 2008 and is headquartered in Wilmington, Delaware.
- Rigid and soft orthopedic bracing systems
- Bone growth stimulators and vascular therapy systems
- Reconstructive joint implants for hip, knee, and shoulder
- Electrical stimulators for pain management
- Therapeutic shoes, inserts, and physical therapy products
Is ENOV a Good Stock to Buy?
UQS Score rates ENOV as Below Average overall.
The most constructive aspects of Enovis's profile sit in its Risk and Valuation pillars, both rated Good — suggesting the stock does not appear to carry excessive financial risk relative to peers, and its current price may not be stretched compared to fundamentals. These two pillars provide a degree of stability to the overall picture.
The Quality and Moat pillars are both rated Weak, indicating that Enovis has not yet demonstrated the durable competitive advantages or consistent financial quality that long-term investors typically seek in a medical device company.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ENOV pay dividends?
No — Enovis Corporation does not currently pay a dividend.
Enovis does not currently pay a dividend. For a company in an active phase of portfolio transformation and integration — having shifted from an industrial conglomerate to a focused medical technology business — retaining capital for reinvestment in product development, acquisitions, and operational scaling is a common strategic choice rather than returning cash to shareholders.
When does ENOV report earnings?
Enovis reports earnings on a quarterly cadence, typical for US-listed equities.
The company's Growth pillar is rated Neutral, reflecting a mixed trajectory as Enovis continues integrating acquisitions and repositioning its business around orthopedic reconstruction and rehabilitation. Execution on cost synergies and revenue growth across its DJO and reconstructive segments will be key factors to watch each quarter.
For the most recent quarter's results and guidance updates, visit Enovis Corporation's investor relations page directly.
ENOV Price History
-68.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Enovis Corporation?
Based on Enovis Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ENOV Long-term Outlook
Enovis's fundamental outlook is shaped by a Neutral Growth profile and Good Risk rating. The company is navigating a meaningful business transformation, and while near-term growth may be uneven, the risk profile suggests the balance sheet is not under acute stress. Progress on integrating its reconstructive joint portfolio and expanding the DJO brand internationally will be central to whether growth accelerates from its current pace.
Growth drivers
- Expansion of reconstructive joint implant portfolio across hip, knee, and shoulder markets
- International distribution growth under the DJO brand
- Aging global population driving demand for orthopedic and rehabilitation products
Key risks
- Weak Moat rating signals limited pricing power versus entrenched orthopedic device competitors
- Integration complexity from the Colfax-to-Enovis transformation could weigh on margins
- Reimbursement and regulatory pressures common across the medical device sector
ENOV vs Peers
Enovis operates in the medical technology and industrials crossover space, and its UQS profile can be viewed alongside other small-cap industrial and specialty companies.
Tennant focuses on commercial cleaning equipment rather than medical devices, representing a different end-market within the broader industrials universe.
China Yuchai is a diesel and natural gas engine manufacturer serving the Chinese commercial vehicle market, with a very different geographic and product focus than Enovis.
Thermon provides industrial heating solutions for process industries, competing in a niche that has no direct overlap with Enovis's orthopedic and rehabilitation focus.
Frequently Asked Questions
What does Enovis Corporation do?
Enovis Corporation develops and distributes medical devices for musculoskeletal conditions. Its products — ranging from orthopedic braces and bone growth stimulators to reconstructive joint implants — are used by orthopedic surgeons, physical therapists, chiropractors, and other healthcare professionals to treat injuries, degenerative diseases, and deformities.
Does ENOV pay dividends?
No, Enovis does not currently pay a dividend. The company is in a phase of business transformation and integration, and management has prioritized reinvesting capital into its medical technology operations rather than distributing cash to shareholders.
When does ENOV report earnings?
Enovis reports financial results on a quarterly cadence, consistent with US-listed public companies. For exact dates and the most recent results, check the investor relations section of the Enovis Corporation website.
Is ENOV a good stock to buy?
UQS Score rates ENOV as Below Average. The Risk and Valuation pillars are rated Good, but the Quality and Moat pillars are both Weak. Whether that profile suits your investment approach depends on your own criteria — the full pillar breakdown is available to UQS Pro members.
Is ENOV overvalued?
The UQS Valuation pillar for ENOV is rated Good, suggesting the stock does not appear significantly overpriced relative to its fundamentals at the time of scoring. Valuation assessments can shift with earnings results and market conditions, so reviewing the full analysis regularly is worthwhile.
How does ENOV compare to its competitors?
Enovis occupies a distinct niche in orthopedic rehabilitation and reconstruction. The peer tickers listed on this page — Tennant Company, China Yuchai, and Thermon Group — operate in different end-markets. For a direct quality comparison, the UQS platform allows side-by-side pillar scoring across tickers.
What is ENOV's market cap bracket?
Enovis Corporation is classified as a small-cap company. This places it in a segment of the market that can offer growth potential but often carries higher volatility and less analyst coverage than large- or mega-cap peers.
Who founded Enovis Corporation?
Enovis traces its roots to Colfax Corporation, which was founded in 1998 by Mitchell Rales and Steven Rales. The company rebranded and refocused as Enovis Corporation to reflect its pivot toward medical technology and orthopedic devices.
Is ENOV a long-term quality investment?
As a long-term quality indicator, ENOV's Below Average UQS Score — driven by Weak Quality and Moat ratings — suggests the company has not yet established the durable competitive advantages typically associated with long-term compounders. The Good Risk and Valuation ratings offer some offset, but the overall profile warrants careful consideration.
What is the main competitive advantage of Enovis Corporation?
Enovis's DJO brand carries meaningful recognition among orthopedic and rehabilitation professionals, and its broad product range across bracing, stimulation, and joint reconstruction creates cross-selling opportunities. However, the UQS Moat pillar is currently rated Weak, indicating these advantages may not yet translate into durable pricing power or market share protection.
What sector does ENOV belong to?
Enovis is classified under the Industrials sector, though its business is firmly rooted in medical technology. The company designs and distributes orthopedic and rehabilitation devices, placing it at the intersection of healthcare and industrial manufacturing.
Is ENOV a growth stock or value stock?
Based on its UQS profile, ENOV sits in an in-between position — the Growth pillar is Neutral and the Valuation pillar is Good. It does not fit neatly into a high-growth or deep-value category, making it a transitional story dependent on execution of its medical technology strategy.
Unlock Full ENOV Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial quality and moat metrics
- ✓Compare ENOV against sector peers side by side
- ✓Track score changes across quarterly earnings cycles
- ✓Screen for stronger-rated medical technology alternatives
- ✓Get the full risk and valuation deep-dive for ENOV
Pro Analysis
ENOV — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 39.0 | 22.4 | 22.0 | 39.5 | 64.3 | 68.8 | +2.7 |
| May 10, 2026 | 36.3 | 0.0 | 22.0 | 51.1 | 36.9 | 100.0 | +0.1 |
| May 8, 2026 | 36.2 | 0.0 | 22.0 | 50.9 | 36.9 | 100.0 | -4.4 |
| Apr 23, 2026 | 40.6 | 19.7 | 22.0 | 50.9 | 64.4 | 68.8 | +0.1 |
| Apr 22, 2026 | 40.5 | 19.4 | 22.0 | 50.9 | 64.4 | 68.8 | -0.1 |
| Apr 18, 2026 | 40.6 | 19.4 | 22.0 | 51.1 | 64.4 | 68.8 | 0.0 |
| Apr 16, 2026 | 40.6 | 19.5 | 22.0 | 51.1 | 64.4 | 68.8 | 0.0 |
| Apr 9, 2026 | 40.6 | 19.7 | 22.0 | 51.1 | 64.4 | 68.8 | -0.1 |
| Apr 3, 2026 | 40.7 | 19.9 | 22.0 | 51.1 | 64.4 | 68.8 | +0.1 |
| Apr 2, 2026 | 40.6 | 19.8 | 22.0 | 51.1 | 64.4 | 68.8 | — |
ENOV — Pillar Breakdown
Quality
— 22.7/100 (25%)Enovis Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 39.5/100 (20%)Enovis Corporation shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 64.3/100 (15%)Enovis Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 68.8/100 (15%)Enovis Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 22/100 (25%)Enovis Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ENOV.
Score Composition
Financial Data
More Stock Analysis
How is the ENOV UQS Score Calculated?
The UQS (Unified Quality Score) for Enovis Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Enovis Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Enovis Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.